Menopause Treatments
Find Menopause Treatments
Medications for Menopause
These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Menopause.
Found 11 Approved Drugs for Menopause
MedroxyPROGESTERone Acetate
Brand Names
Depo-Provera, Depo-SubQ Provera, MedroxyPROGESTERone, Premphase, Prempro, Provera
MedroxyPROGESTERone Acetate
Brand Names
Depo-Provera, Depo-SubQ Provera, MedroxyPROGESTERone, Premphase, Prempro, Provera
Form: Injection, Tablet, Kit
Method of administration: Subcutaneous, Oral, Intramuscular
FDA approval date: June 03, 1959
Classification: Progestin
Depo-Provera CI is indicated for use by females of reproductive potential to prevent pregnancy. Depo-Provera CI is a progestin indicated for use by females of reproductive potential to prevent pregnancy. ( 1 ) Limitations of Use: The use of Depo-Provera CI is not recommended as a long-term (i.e., longer than 2 years) birth control method unless other options are considered inadequate. ( 1.
Norethindrone Acetate
Brand Names
24FE, Abigale, Activella, Affodel, Alyacen, Aranelle, Aurovela, Aurovela 24, Balziva, Blisovi, Blisovi 24, Briellyn, Camila, Cyonanz, Dasetta, Deblitane, Emzahh, ERRIN, Etyqa, Feirza, Femlyv, Finzala, Fyavolv, Galbriela, Gallifrey, Hailey, Hailey 24, Incassia, Jencycla, Jinteli, Junel, Junel 21, Kaitlib, Loestrin, Loestrin 21, Lopreeza, Luizza, Lyleq, Meleya, Melodetta 24, Mibelas 24, Microgestin, Microgestin 24, Mimvey, Myfembree, Necon, Nexesta, Norethindrone, Nortrel, Nortrel 21, Nortrel 28, Nylia, Orquidea, OSHIH, Philith, Rhuzdah, Sharobel, Tarina, Tarina 24, Taytulla, Tri-Legest, Vyfemla, Wera, Wymzya, XARAH, Xelria, Zenchent
Norethindrone Acetate
Brand Names
24FE, Abigale, Activella, Affodel, Alyacen, Aranelle, Aurovela, Aurovela 24, Balziva, Blisovi, Blisovi 24, Briellyn, Camila, Cyonanz, Dasetta, Deblitane, Emzahh, ERRIN, Etyqa, Feirza, Femlyv, Finzala, Fyavolv, Galbriela, Gallifrey, Hailey, Hailey 24, Incassia, Jencycla, Jinteli, Junel, Junel 21, Kaitlib, Loestrin, Loestrin 21, Lopreeza, Luizza, Lyleq, Meleya, Melodetta 24, Mibelas 24, Microgestin, Microgestin 24, Mimvey, Myfembree, Necon, Nexesta, Norethindrone, Nortrel, Nortrel 21, Nortrel 28, Nylia, Orquidea, OSHIH, Philith, Rhuzdah, Sharobel, Tarina, Tarina 24, Taytulla, Tri-Legest, Vyfemla, Wera, Wymzya, XARAH, Xelria, Zenchent
Form: Tablet, Kit
Method of administration: Oral
FDA approval date: May 25, 2001
Classification: Progestin
Charlotte 24 Fe is indicated for use by females of reproductive age to prevent pregnancy. The efficacy of Charlotte 24 Fe in women with a body mass index (BMI) of more than 35 kg/m 2 has not been evaluated. Charlotte 24 Fe is a combination of norethindrone acetate, a progestin, and ethinyl estradiol, an estrogen, indicated for use by females of reproductive potential to prevent pregnancy ( 1 ), The efficacy in females of reproductive potential with a body mass index of more than 35 kg/m 2 has not been evaluated ( 1.
Osphena
Generic Name
Ospemifene
Osphena
Generic Name
Ospemifene
Form: Tablet
Method of administration: Oral
FDA approval date: April 01, 2023
Classification: Estrogen Agonist/Antagonist
OSPHENA is indicated for: OSPHENA is an estrogen agonist/antagonist indicated for: The treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause.
Veozah
Generic Name
Fezolinetant
Veozah
Generic Name
Fezolinetant
Form: Tablet
Method of administration: Oral
FDA approval date: May 12, 2023
Classification: Neurokinin 3 Receptor Antagonist
VEOZAH ® is indicated for the treatment of moderate to severe vasomotor symptoms due to menopause. VEOZAH is a neurokinin 3 (NK3) receptor antagonist indicated for the treatment of moderate to severe vasomotor symptoms due to menopause. ( 1 )
Paroxetine
Brand Names
Brisdelle, Paxil
Paroxetine
Brand Names
Brisdelle, Paxil
Form: Tablet, Suspension, Capsule
Method of administration: Oral
FDA approval date: July 30, 2003
Classification: Serotonin Reuptake Inhibitor
BRISDELLE is indicated for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause. Limitations of Use: BRISDELLE is not indicated for the treatment of any psychiatric condition. BRISDELLE has a lower recommended paroxetine dosage than that used to treat major depressive disorder, obsessive compulsive disorder, panic disorder, generalized anxiety disorder, social anxiety disorder, and post-traumatic stress disorder. The safety and effectiveness of the lower BRISDELLE dosage has not been established for any psychiatric condition. Patients who require paroxetine for treatment of a psychiatric condition should discontinue BRISDELLE and initiate a paroxetine-containing product that is indicated for such use. BRISDELLE is a selective serotonin reuptake inhibitor (SSRI) indicated for the treatment of moderate to severe vasomotor symptoms associated with menopause (VMS) ( 1 ) Limitations of Use : BRISDELLE is not indicated for the treatment of any psychiatric condition ( 1 )
Showing 1-5 of 11
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances